Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
Gain Therapeutics (Nasdaq: GANX) announced a virtual webinar on September 30, 2024, at 8:30 am ET to discuss results from the Phase 1 study of GT-02287, their novel GCase-targeting small molecule therapy for Parkinson's disease. The company will present positive results recently shared at the International Congress of Parkinson's Disease and Movement Disorders® (MDS) and outline the design of an upcoming Phase 1b trial in Parkinson's disease patients.
The webinar will include a live Q&A session following formal presentations. Interested parties can register for the event or join via the company's website. A replay will be available in the News and Events section of the Gain Therapeutics website after the event.
Gain Therapeutics (Nasdaq: GANX) ha annunciato un webinar virtuale per il 30 settembre 2024, alle 8:30 ora ET, per discutere i risultati dello studio di Fase 1 di GT-02287, la loro nuova terapia a piccole molecole mirata a GCase per il morbo di Parkinson. L'azienda presenterà risultati positivi recentemente condivisi al Congresso Internazionale sulla Malattia di Parkinson e i Disturbi del Movimento® (MDS) e illustrerà il design di un prossimo trial di Fase 1b per pazienti affetti da morbo di Parkinson.
Il webinar includerà una sessione di domande e risposte dal vivo dopo le presentazioni formali. Le parti interessate possono registrarsi per l'evento o partecipare tramite il sito web dell'azienda. Una registrazione sarà disponibile nella sezione Notizie ed Eventi del sito di Gain Therapeutics dopo l'evento.
Gain Therapeutics (Nasdaq: GANX) anunció un seminario web virtual el 30 de septiembre de 2024, a las 8:30 a.m. ET, para discutir los resultados del estudio de Fase 1 de GT-02287, su novedosa terapia de pequeñas moléculas dirigida a GCase para la enfermedad de Parkinson. La empresa presentará resultados positivos compartidos recientemente en el Congreso Internacional de Enfermedad de Parkinson y Trastornos del Movimiento® (MDS) y delineará el diseño de un próximo ensayo de Fase 1b en pacientes con enfermedad de Parkinson.
El seminario web incluirá una sesión de preguntas y respuestas en vivo después de las presentaciones formales. Las partes interesadas pueden registrarse para el evento o unirse a través del sitio web de la empresa. Una repetición estará disponible en la sección de Noticias y Eventos del sitio web de Gain Therapeutics después del evento.
Gain Therapeutics (Nasdaq: GANX)는 2024년 9월 30일 오전 8:30 ET에 파킨슨병에 대한 그들의 새로운 GCase 타겟 소분자 치료제인 GT-02287의 1상 연구 결과를 논의하는 가상 웨비나를 발표했습니다. 이 회사는 최근 MDS(파킨슨병 및 운동장애 국제학회)에서 공유된 긍정적인 결과를 발표하고, 파킨슨병 환자에 대한 예정된 1b상 시험의 설계를 설명할 것입니다.
이번 웨비나는 공식 발표 후 실시간 질의응답 세션이 포함될 예정입니다. 관심이 있는 분들은 이벤트에 등록하거나 회사의 웹사이트를 통해 참여할 수 있습니다. 이벤트 후 Gain Therapeutics 웹사이트의 뉴스 및 이벤트 섹션에서 다시 볼 수 있습니다.
Gain Therapeutics (Nasdaq: GANX) a annoncé un webinaire virtuel le 30 septembre 2024 à 8h30 ET pour discuter des résultats de l'étude de Phase 1 de GT-02287, leur nouvelle thérapie par petites molécules ciblant GCase pour la maladie de Parkinson. L'entreprise présentera des résultats positifs récemment partagés lors du Congrès International sur la Maladie de Parkinson et les Troubles du Mouvement® (MDS) et décrira le design d'un prochain essai de Phase 1b chez des patients atteints de la maladie de Parkinson.
Le webinaire inclura une session de questions-réponses en direct après les présentations formelles. Les parties intéressées peuvent s'inscrire à l'événement ou participer via le site Web de l'entreprise. Un enregistrement sera disponible dans la section Actualités et Événements du site Web de Gain Therapeutics après l'événement.
Gain Therapeutics (Nasdaq: GANX) kündigte ein virtuelles Webinar für den 30. September 2024 um 8:30 Uhr ET an, um die Ergebnisse der Phase-1-Studie von GT-02287, ihrer neuartigen GCase-zielgerichteten kleinen Molekültherapie für Morbus Parkinson, zu diskutieren. Das Unternehmen wird positive Ergebnisse präsentieren, die kürzlich auf dem Internationalen Kongress für Parkinsonkrankheit und Bewegungsstörungen® (MDS) geteilt wurden, und das Design einer bevorstehenden Phase-1b-Studie bei Parkinson-Patienten skizzieren.
Das Webinar wird eine Live-Fragerunde nach den formellen Präsentationen beinhalten. Interessierte können sich für die Veranstaltung anmelden oder über die Website des Unternehmens teilnehmen. Eine Wiederholung wird nach der Veranstaltung im Bereich Neuigkeiten und Veranstaltungen auf der Website von Gain Therapeutics verfügbar sein.
- Positive results from Phase 1 study of GT-02287 for Parkinson's disease
- Advancement to Phase 1b trial planning stage
- Presentation of results at a major international congress (MDS)
- None.
Company To Discuss Positive Results Presented at the International MDS Congress and the Design of Phase 1b Trial in Parkinson’s Disease Patients
Event Will Be Held on Monday, September 30, 2024, at 8:30 am ET
BETHESDA, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it is holding a webinar to discuss data from the Phase 1 study of GT-02287, a novel GCase-targeting small molecule therapy for Parkinson’s disease, recently presented in a late-breaker at the International Congress of Parkinson’s Disease and Movement Disorders® (MDS). The Company will also discuss the design of a planned Phase 1b trial of GT-02287 in Parkinson’s disease patients.
Webinar Details
Date: Monday, September 30, 2024
Time: 8:30 am ET
Register for the event HERE or join the conference call through the News and Events section of the Company website at https://www.gaintherapeutics.com/investors-media/news-events.
A live question and answer session will follow the formal presentations. A replay of the call will be available in the News and Events section of the Company website after the event.
About GT-02287
Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease with or without a GBA1 mutation. The orally administered, brain-penetrant small molecule is an allosteric protein modulator that restores the function of the lysosomal protein enzyme glucocerebrosidase (GCase) which becomes misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related stress factors. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, and improved motor function and cognitive performance. Additionally, GT-02287 significantly reduced plasma neurofilament light chain (NfL) levels, an emerging biomarker for neurodegeneration.
Compelling preclinical data in mouse models of GBA1-PD, including that presented at FENS Forum 2024 in June describing improvement in cognitive performance in addition to motor performance after administration of GT-02287, suggests that GT-02287 may have the potential to slow the progression of Parkinson’s disease.
Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 for the treatment of Parkinson’s disease with or without a GBA1 mutation, is currently being evaluated in a Phase 1 clinical trial.
Leveraging AI-supported structural biology, proprietary algorithms, and supercomputer-powered physics-based models, the company’s Magellan™ drug discovery platform can identify novel allosteric binding sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current technologies. Its AI and machine-learning tools and virtual screening capabilities leverage the emerging on-demand compound libraries covering vast chemical spaces of over five trillion compounds to identify and select suitable small molecule hits for experimental validation.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with market conditions and the satisfaction of customary closing conditions related to the offering and uncertainties related to the offerings and the use of proceeds from the offerings. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company’s Form 10-K for the year ended December 31, 2023 and Form 10-Q for the quarter ended June 30, 2024.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Apaar Jammu and Chuck Padala
ajammu@gaintherapeutics.com
chuck@lifesciadvisors.com
Media Contacts:
Russo Partners
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
FAQ
What is the purpose of Gain Therapeutics' upcoming webinar on September 30, 2024?
What is GT-02287 and what is it being developed for by Gain Therapeutics (GANX)?
Where were the Phase 1 results of GT-02287 recently presented by Gain Therapeutics (GANX)?
What is the next clinical trial phase planned for GT-02287 by Gain Therapeutics (GANX)?
